OCS™ Lung

The only FDA-approved device for utilized lung transplant. Currently under FDA review for unutilized lung transplant 

The Only FDA-approved, Portable, Lung Perfusion System For Utilized Donor Lungs

The OCS Lung is a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state – allowing physicians to assess and improve the condition of lungs between the donor and recipient sites.

The Benefits of OCS Lung

INSPIRE TRIAL

The OCS Lung is FDA approved for use with utilized donor lungs

Improved post-transplant outcomes compared to cold storage

~50% reduction of primary graft dysfunction (PGD) grade 3*

Significantly expanded organ retrieval range while limiting ischemic time

Reduction of PGD3 with OCS

*PGD3 is the most common and severe clinical complication of lung transplantation and is a predictor of short and long-term morbidity and mortality post transplantation.
TransMedics OCS Lung significantly reduced PGD3 vs control group in the INSPIRE Trial.

Significant Reduction of PGD3 within 72 Hours

EXPAND TRIAL

The OCS Lung is currently under FDA review for use with unutilized donor lungs

International pivotal trial to evaluate the Organ Care System for use with unutilized donor lungs that may not meet current standard acceptance criteria for transplantation.

  • 79 patients were enrolled worldwide
  • Types of donors used

– Older donors ≥55 years – 39%
– DCD donors – 33%
– Ischemic time >6 hours – 32%
– PaO2/FiO2 ratio ≤300 mmHg –25% 
– 20 patients had 2+ indications

  • UNOS data showed donor lungs used for the OCS Lung EXPAND Trial had been declined for transplantation on average 35 times by other transplant centers before reaching an OCS Trial Center
  • Primary effectiveness endpoints:

– Patient survival at 30 days post transplant
– Absence of Primary Graft Dysfunction (PGD) grade 3 during the first 72 hours post transplant

Locate an OCS Lung Center

The OCS Lung is FDA approved for use with utilized donor lungs. It is currently under FDA review for use with unutilized donor lungs. The OCS Lung is CE marked and commercially available in Europe and Australia.

Massachusetts General Hospital

Main Campus
55 Fruit Street
Boston, MA 02114

(617) 726-2000

Houston Methodist Hospital

6565 Fannin St
Houston, TX 77030

(713) 790-3311

Johns Hopkins Hospital

1800 Orleans St
Baltimore, MD 21287

(410) 955-5000

University of Minnesota Medical Center

909 Fulton St. SE
Minneapolis, MN 55455

(612) 273-8383

University of CA San Francisco Med Center

505 Parnassus Ave
San Francisco, CA 94143

(415) 353-1664

Duke University Medical Center

10 Duke Medicine Circle
Durham, NC 27710

(919) 372-3345 

Temple University Hospital

3401 N Broad St
Philadelphia, PA 19140

(215) 707-2000 

St Luke's Baylor

6720 Bertner Ave
Houston, TX 77030

(832) 355-1000

St. Joseph's (Dignity Health)

350 W Thomas Rd
Phoenix, AZ 85013

(602) 406-3000

University of Virginia (UVA)

1215 Lee St
Charlottesville, VA 22903

(434) 924-0000

UCLA Medical Center

757 Westwood Plaza
Los Angeles, CA 90095

(310) 825-9111

MCW/Froedtert

9200 W Wisconsin Ave
Milwaukee, WI 53226

(414) 805-3000

Stanford Medical Center

300 Pasteur Drive
Stanford, CA 94305 

(650) 498-7878

The OCS Lung, OCS Heart and OCS Liver are all CE marked devices.
The OCS Lung is an FDA-approved device for utilized donor lungs. The OCS Heart and OCS Liver devices are investigational devices and, therefore, are limited by federal law to investigational use in the US.

ONLY
multi-organ platform

SUBSTANTIAL
body of clinical evidence